ArticleAmerican journal of obstetrics and gynecology2016

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

Stefania Bellone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.